About Biohaven Pharmaceutical
Biohaven Pharmaceutical is a company based in New Haven (United States) founded in 2014 was acquired by Pfizer in May 2022.. Biohaven Pharmaceutical has raised $84.1 million across 3 funding rounds from investors including Pfizer, RA Capital and Portage Biotech. Biohaven Pharmaceutical has completed 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher. Biohaven Pharmaceutical offers products and services including Nurtec ODT and Zavzpret. Biohaven Pharmaceutical operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter New Haven, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biohaven Pharmaceuticals Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$84.1 M (USD)
in 3 rounds
-
Latest Funding Round
-
Investors
Pfizer
& 10 more
-
Employee Count
Employee Count
-
Investments & Acquisitions
Channel Bio-Sciences
& 2 more
-
Acquired by
Pfizer
(May 10, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biohaven Pharmaceutical
Biohaven Pharmaceutical is a publicly listed company on the NYSE with ticker symbol BHVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Biohaven Pharmaceutical
Biohaven Pharmaceutical offers a comprehensive portfolio of products and services, including Nurtec ODT and Zavzpret. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral dissolving tablet for migraine treatment and relief.
Nasal spray option for effective migraine management.
Unlock access to complete
Unlock access to complete
Funding Insights of Biohaven Pharmaceutical
Biohaven Pharmaceutical has successfully raised a total of $84.1M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Last Round
-
First Round
First Round
(11 Aug 2015)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2017 | Amount | Series C - Biohaven Pharmaceutical | Valuation |
investors |
|
| Nov, 2016 | Amount | Series C - Biohaven Pharmaceutical | Valuation | Venrock | |
| Aug, 2015 | Amount | Series A - Biohaven Pharmaceutical | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biohaven Pharmaceutical
Biohaven Pharmaceutical has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, RA Capital and Portage Biotech. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biohaven Pharmaceutical
Biohaven Pharmaceutical has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Channel Bio-Sciences, Kleo Pharmaceuticals and Priorityreviewvoucher. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Healthcare consulting services are provided to industry clients.
|
2016 | ||||
|
Developing a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and infectious diseases
|
2015 | ||||
|
Priority review vouchers are supplied for expedited drug approvals.
|
0 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Biohaven Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biohaven Pharmaceutical Comparisons
Competitors of Biohaven Pharmaceutical
Biohaven Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Drugs for CNS disorders are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biohaven Pharmaceutical
Frequently Asked Questions about Biohaven Pharmaceutical
When was Biohaven Pharmaceutical founded?
Biohaven Pharmaceutical was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Where is Biohaven Pharmaceutical located?
Biohaven Pharmaceutical is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Is Biohaven Pharmaceutical a funded company?
Biohaven Pharmaceutical is a funded company, having raised a total of $84.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $4.1M, raised on Aug 11, 2015.
What does Biohaven Pharmaceutical do?
Biohaven Pharmaceutical was founded in 2014 in New Haven, United States, within the biotechnology sector. Therapies targeting neurological and neuropsychiatric conditions are developed by the company. The pipeline includes BHV-0223, a glutamate-modulating agent under FDA review, along with BHV-4157 for spinocerebellar ataxia treatment and SHV-5000i, an NMDA receptor antagonist for post-traumatic stress disorder and treatment-resistant depression. Operations focus on drug development for these areas.
Who are the top competitors of Biohaven Pharmaceutical?
Biohaven Pharmaceutical's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and PureTech Health.
What products or services does Biohaven Pharmaceutical offer?
Biohaven Pharmaceutical offers Nurtec ODT and Zavzpret.
Is Biohaven Pharmaceutical publicly traded?
Yes, Biohaven Pharmaceutical is publicly traded on NYSE under the ticker symbol BHVN.
How many acquisitions has Biohaven Pharmaceutical made?
Biohaven Pharmaceutical has made 3 acquisitions, including Channel Bio-Sciences, Kleo Pharmaceuticals, and Priorityreviewvoucher.
Who are Biohaven Pharmaceutical's investors?
Biohaven Pharmaceutical has 11 investors. Key investors include Pfizer, RA Capital, Portage Biotech, Venrock, and Aisling Capital.
What is Biohaven Pharmaceutical's ticker symbol?
The ticker symbol of Biohaven Pharmaceutical is BHVN on NYSE.